Eli Lilly and Co at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2021 / 12:50PM GMT
Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MD

Great. Good morning, everybody. I'm Terence Flynn, the U.S. biopharma analyst at Goldman Sachs, and we're very pleased to be hosting Eli Lilly today at our virtual healthcare conference.

Joining us today from the company, we have Anne White, who is President of Lilly Oncology; and Jake Van Naarden, who is CEO of Loxo Oncology at Lilly. Thank you both so much for joining us today. Really appreciate the time.

Questions and Answers:

Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MD

As I know it's an extremely busy time of the year. You're post the ASCO Conference. Maybe to start, I thought a good place would be just to give us an overview of kind of the company's current strategy here in oncology.

What's differentiated about your approach versus other players? And then how are you thinking about the different verticals, targeted oncology versus IO, as obviously there's a lot of ongoing efforts there at the company.

Jacob S. Van Naarden<
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot